Cartesian Therapeutics (RNAC) Income towards Parent Company: 2015-2025
Historic Income towards Parent Company for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$19.5 million.
- Cartesian Therapeutics' Income towards Parent Company fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Income towards Parent Company is -$19.5 million, which was up 2.72% from -$20.1 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Income towards Parent Company peaked at $15.0 million during Q2 2024, and registered a low of -$196.7 million during Q4 2023.
- Over the past 3 years, Cartesian Therapeutics' median Income towards Parent Company value was -$18.0 million (recorded in 2023), while the average stood at -$30.7 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 5,505.67% in 2022, then plummeted by 3,437.15% in 2023.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Income towards Parent Company stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then slumped by 3,437.15% to -$196.7 million in 2023, then soared by 87.66% to -$24.3 million in 2024, then slumped by 30.10% to -$19.5 million in 2025.
- Its Income towards Parent Company was -$19.5 million in Q3 2025, compared to -$20.1 million in Q2 2025 and -$19.9 million in Q1 2025.